These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8805938)

  • 21. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
    King K; Younes A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):14-22. PubMed ID: 10697039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
    Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS
    Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
    [No Abstract]   [Full Text] [Related]  

  • 24. Advances in chemotherapy for Hodgkin's and non-Hodgkin's lymphomas.
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):1-73. PubMed ID: 3399906
    [No Abstract]   [Full Text] [Related]  

  • 25. Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial.
    Keller JW; Omura GA; Gams RA; Bartolucci AA
    Am J Clin Oncol; 1987 Jun; 10(3):194-5. PubMed ID: 3591737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
    Enblad G; Glimelius B; Hagberg H; Lindemalm C
    Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE.
    Pinheiro KV; Hungria VT; Ficker ES; Valduga CJ; Mesquita CH; Maranhão RC
    Cancer Chemother Pharmacol; 2006 May; 57(5):624-30. PubMed ID: 16133527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996.
    van Spronsen DJ; Janssen-Heijnen ML; Breed WP; Coebergh JW
    Ann Hematol; 1999 Jul; 78(7):315-9. PubMed ID: 10466443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Low grade non-Hodgkin's lymphoma after combined therapy for Hodgkin's disease].
    Raya Sánchez JM; González Brito G; Hernández Nieto L; Brito Barroso ML; Alvarez Argüelles H; Jorge Hernández JA; Martín Herrera A
    Sangre (Barc); 1994 Dec; 39(6):461-4. PubMed ID: 7855699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of chylomicron-like emulsions in patients with Hodgkin's and with non-Hodgkin's lymphoma.
    Gonçalves RP; Hungria VT; Chiattone CS; Pozzi DB; Maranhão RC
    Leuk Res; 2003 Feb; 27(2):147-53. PubMed ID: 12526920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
    Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
    Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of primary refractory Hodgkin's disease treated successfully with paclitaxel.
    Kallab AM; Dainer P
    Am J Hematol; 1999 Mar; 60(3):248. PubMed ID: 10072122
    [No Abstract]   [Full Text] [Related]  

  • 36. Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18.
    Smith M; Borghaei H
    Cancer Invest; 2005; 23(6):572. PubMed ID: 16203667
    [No Abstract]   [Full Text] [Related]  

  • 37. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
    Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA
    Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.
    Zinzani PL
    Ann Oncol; 2003; 14 Suppl 1():i43-5. PubMed ID: 12736231
    [No Abstract]   [Full Text] [Related]  

  • 39. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
    Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972.
    Rybak ME; Anderson JR; Poulin RF; Amrein PC; Canellos GP; Gottlieb AJ
    Cancer Treat Rep; 1986 Oct; 70(10):1233-4. PubMed ID: 3530451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.